| An update of safety of clinically used atypical antipsychotics L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, ... Expert opinion on drug safety 15 (10), 1329-1347, 2016 | 141 | 2016 |
| Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic … A de Bartolomeis, EF Buonaguro, F Iasevoli Psychopharmacology 225, 1-19, 2013 | 110 | 2013 |
| Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to … A de Bartolomeis, R Balletta, S Giordano, EF Buonaguro, G Latte, ... Psychiatry research 210 (2), 387-395, 2013 | 108 | 2013 |
| Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and … A de Bartolomeis, C Sarappa, EF Buonaguro, F Marmo, A Eramo, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 46, 1-12, 2013 | 80 | 2013 |
| Treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions C Tomasetti, F Iasevoli, EF Buonaguro, D De Berardis, M Fornaro, ... International Journal of Molecular Sciences 18 (1), 135, 2017 | 73 | 2017 |
| Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder M Mereu, G Contarini, EF Buonaguro, G Latte, F Managò, F Iasevoli, ... Neuropharmacology 121, 179-194, 2017 | 63 | 2017 |
| The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment F Iasevoli, C Tomasetti, E F. Buonaguro, A de Bartolomeis Current neuropharmacology 12 (3), 219-238, 2014 | 61 | 2014 |
| Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or … F Iasevoli, A Valchera, E Di Giovambattista, M Marconi, MP Rapagnani, ... Journal of affective disorders 151 (2), 540-550, 2013 | 60 | 2013 |
| The emerging role of dopamine–glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: implications for treatment A de Bartolomeis, EF Buonaguro, F Iasevoli, C Tomasetti Journal of psychopharmacology 28 (6), 505-526, 2014 | 54 | 2014 |
| Immediate-early genes modulation by antipsychotics: translational implications for a putative gateway to drug-induced long-term brain changes A De Bartolomeis, EF Buonaguro, G Latte, R Rossi, F Marmo, F Iasevoli, ... Frontiers in behavioral neuroscience 11, 240, 2017 | 53 | 2017 |
| Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews M Fornaro, D De Berardis, G Perna, M Solmi, N Veronese, L Orsolini, ... BioMed Research International 2017 (1), 3084859, 2017 | 43 | 2017 |
| Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol A de Bartolomeis, F Marmo, EF Buonaguro, R Rossi, C Tomasetti, ... European Neuropsychopharmacology 23 (11), 1516-1529, 2013 | 43 | 2013 |
| New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, F Vellante, ... Expert Review of Neurotherapeutics 16 (5), 483-495, 2016 | 40 | 2016 |
| The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions M Fornaro, M Solmi, N Veronese, D De Berardis, EF Buonaguro, ... International Review of Psychiatry 29 (5), 425-435, 2017 | 37 | 2017 |
| Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, M Fornaro, ... CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders) 16 …, 2017 | 35 | 2017 |
| Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles … A de Bartolomeis, F Iasevoli, F Marmo, EF Buonaguro, A Eramo, R Rossi, ... European Neuropsychopharmacology 25 (4), 566-582, 2015 | 35 | 2015 |
| Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling EF Buonaguro, F Iasevoli, F Marmo, A Eramo, G Latte, C Avagliano, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 76, 29-41, 2017 | 24 | 2017 |
| Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review F Iasevoli, A Barone, EF Buonaguro, L Vellucci, A de Bartolomeis Expert Opinion on Drug Safety 19 (11), 1419-1444, 2020 | 22 | 2020 |
| Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia F Iasevoli, EF Buonaguro, C Sarappa, F Marmo, G Latte, R Rossi, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 54, 299-314, 2014 | 22 | 2014 |
| The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular “Lego” in the pathophysiology of psychiatric disorders. A systematic … A de Bartolomeis, A Barone, EF Buonaguro, C Tomasetti, L Vellucci, ... Neuroscience & Biobehavioral Reviews 136, 104596, 2022 | 21 | 2022 |